mutLBSgeneDB |
Gene summary for KCNK10 |
![]() |
Basic gene Info. | Gene symbol | KCNK10 |
Gene name | potassium channel, subfamily K, member 10 | |
Synonyms | K2p10.1|PPP1R97|TREK-2|TREK2 | |
Cytomap | UCSC genome browser: 14q31.3 | |
Type of gene | protein-coding | |
RefGenes | NM_021161.4, NM_138317.2,NM_138318.2, | |
Description | 2P domain potassium channel TREK2TREK-2 K(+) channel subunitTWIK-related K+ channel 2outward rectifying potassium channel protein TREK-2potassium channel TREK-2potassium channel subfamily K member 10protein phosphatase 1, regulatory subunit 97 | |
Modification date | 20141207 | |
dbXrefs | MIM : 605873 | |
HGNC : HGNC | ||
Ensembl : ENSG00000100433 | ||
HPRD : 12061 | ||
Vega : OTTHUMG00000170743 | ||
Protein | UniProt: P57789 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_KCNK10 | |
BioGPS: 54207 | ||
Pathway | NCI Pathway Interaction Database: KCNK10 | |
KEGG: KCNK10 | ||
REACTOME: KCNK10 | ||
Pathway Commons: KCNK10 | ||
Context | iHOP: KCNK10 | |
ligand binding site mutation search in PubMed: KCNK10 | ||
UCL Cancer Institute: KCNK10 | ||
Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. |
![]() |
GO ID | GO Term | PubMed ID |
Top |
Ligand binding site mutations for KCNK10 |
![]() |
LBS | AAchange of nsSNV | Cancer type | # samples | T276 | T276M | COAD | 1 | T276 | T276M | KIRC | 1 | V271 | V272F | LUAD | 1 | L274 | L274V | LUSC | 1 | G171 | G171A | OV | 1 | V248 | V248M | PRAD | 1 | G280 | D281N | SKCM | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for KCNK10 |
![]() Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
![]() ![]() |
![]() |
![]() Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | G171 | G171A | 0.083504513 | L274 | L274V | -1.1227835 | T276 | T276M | -0.87590741 | G280 | D281N | -0.77814444 | V248 | V248M | -0.62003065 | V271 | V272F | -0.23313671 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
![]() |
Top |
Differential gene expression and gene-gene network for KCNK10 |
![]() |
![]() |
Top |
Top |
Phenotype information for KCNK10 |
![]() |
Disease ID | Disease name | # PubMed | Association type |
![]() |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for KCNK10 |
![]() Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
![]() |
![]() |
Drug status | DrugBank ID | Name | Type | Drug structure |
![]() |
![]() |
![]() |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
Top |
Conservation information for LBS of KCNK10 |
![]() |
LBS | AA sequence | # species | Species |
![]() |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |